Coulter Partners places Chief Executive Officer at Alethio Therapeutics
LONDON, UK – January 7, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Alethio Therapeutics – formerly known as Alethiomics – and is pleased to announce the placement of Dr. Rohit Batta as Chief Executive Officer.
Alethio Therapeutics is a biotech company advancing therapies designed to help people with Myeloproliferative Neoplasms (MPNs) live longer, healthier, and more fulfilling lives. Backed by deep scientific and clinical expertise, the Company is focused on translating its discovery insights into a pipeline of precision, disease-modifying therapies.
Rohit Batta joins Alethio Therapeutics from Ferring Ventures, where he served as Managing Director and Head of the group company. Previously, he was Chief Medical Officer at Vicore Pharma and also held senior leadership roles at GSK, where he led the clinical strategy for haemoglobinopathy gene therapies and played a pivotal role in launching the world’s first gene therapy for a pediatric rare disease – an achievement that earned his team a prestigious Prix Galien award. Rohit brings 20 years of industry experience in translating breakthrough science into therapies and strategic partnerships. He began his career as a physician in the UK’s National Health Service, and has worked across multiple clinical specialties including oncology.
“With no curative options, MPNs expose patients to ongoing risk of disease evolution and poor outcomes,” said Rohit Batta, CEO. “Alethio Therapeutics is entering a new chapter with the ambition and leadership to deliver the first disease-modifying therapies for MPNs. While current treatments are largely symptomatic, our unique expertise and approach enable us to directly target the drivers of disease progression, with the aim of shifting the treatment paradigm and transforming outcomes for patients. It is an exciting time to be joining Alethio Therapeutics, and I look forward to leading our team as we advance our pipeline.”
“We set out to find a CEO who was a strong business leader, possessing acute commercial acumen alongside the ability to deeply understand our innovative science to guide our strategy through the next phase of growth,” said Mark Throsby, non-executive Director at Alethio Therapeutics. “Coulter Partners immediately grasped this brief. Their diligent search successfully identified a visionary who not only met all our criteria, but who also clicked immediately with the founders and the Board. We appreciate their expertise in delivering this critical placement.”
[ENDS]
Notes to editors:
About Alethio Therapeutics
Alethio Therapeutics is pioneering the development of disease-modifying therapies for patients with chronic blood cancers, with the aim of helping them live fully, freely, and well. Formerly known as Alethiomics, Alethio Therapeutics is specifically focused on myeloproliferative neoplasms (MPNs), a group of chronic, incurable, and ultimately fatal blood cancers, where currently approved treatments – such as JAK inhibitors – are not selectively targeting disease-driving cells and primarily offer symptomatic relief. The Company’s lead programme, AT-01, is based on a novel target identified on MPN mutant stem cells that drive MPN disease progression. Alethio Therapeutics has generated compelling preclinical data for AT-01 demonstrating elimination of targeted cells. The Company is leveraging its expertise in MPN biology, bone marrow organoids, and ADC technology to advance AT-02, an ADC candidate targeting mutant CALR – a key driver mutation in MPNs – currently in preclinical development. Alethio Therapeutics’ proprietary discovery engine, ARTEMIS, integrates access to leading MPN biobanks, single-cell sequencing, organoids, and bioinformatics to de-risk first-in-human trials and identify new mutant drivers, expanding therapeutic reach and market potential. Alethio Therapeutics is led by a highly experienced team and board, with Oxford Science Enterprises as its anchor investor.
About Coulter Partners
We are executive search and leadership development specialists working to build a better future. As advisors and consultants to companies at the cutting edge of Health, Science, and Technology, we are united by our mission to build teams that change the world. Operating uniquely as one global team, we have honed our expertise, platform, and data for over two decades, working across three continents, and in 40 countries. Applying what we learn through our work with boards, leadership teams, and investors in the world’s most innovative companies, we bring together and develop the right people at the right time to propel them to achieve their worthwhile goals.
